Bruker Corporation (BRKR) News
Follow Bruker Corporation (BRKR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Bruker Price Target Raised to $80.00/Share From $60.00 by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 04:33 PM UTC
L
Bruker Advances Functional Proteomics With Novel Timsultra Aip And Timsomni Workflows For Drug Discovery & Development And Disease Biology Research
Bruker Corporation NASDAQ:BRKR
NEWS | Sep 28, 2026, 11:05 AM UTC
H
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE: LUXE ) rose sharply after the company reported fourth-quarter results. LuxExperience reporte
LIVE | Sep 16, 2026, 01:57 PM UTC
L
UBS raises Bruker price target to $65, maintains Neutral
UBS maintains a Neutral rating on Bruker and raises its price target to $65.00 per share from $45.00, according to Benzinga.
EQUITY | Sep 09, 2026, 05:53 PM UTC
L
Bruker shares fall 6.3% after UBS starts coverage
Bruker shares dropped 6.3% in the afternoon session after UBS initiated coverage with a Neutral rating and a $65 price target.
EQUITY | Sep 09, 2026, 04:55 PM UTC
L
BRKR cites strong order growth and AI automation for future leadership
BRKR says strong order growth in China and tech markets, alongside AI-driven automation, supports future leadership, while revenue timing is affected by complex contracts. Integration of NMR and mass spectrometry systems
GEOPOLITICS | Sep 09, 2026, 01:38 PM UTC
L
BRKR: Integration of advanced technologies and deep tech drives growth, with strong order momentum
The conference highlighted integration of NMR and mass spectrometry, expansion into organ-on-a-chip via Mimetas, and strong growth in deep tech and proteomics. Financials showed EPS outperformance and robust order growth
EARNINGS | Sep 09, 2026, 12:57 PM UTC
L
Bruker leadership to present at upcoming healthcare investor conferences
Bruker Corporation says senior leadership will present at Wells Fargo’s 21st Annual Healthcare Conference (Boston) on Wednesday, September 9, 2026 at 8:00 a.m. Eastern Time.
EQUITY | Sep 08, 2026, 05:21 PM UTC
H
S&P 500 Hits Record Highs, Palantir Jumps 27%: Stock Market Today
U.S. equities powered to fresh record highs by midday Tuesday as blowout guidance from Palantir Technologies Inc. (NASDAQ: PLTR ) and a Caterpillar Inc. (NYSE: CAT ) earnings beat reignited the AI trade, while crude oil
EARNINGS | Aug 04, 2026, 05:07 PM UTC
L
Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs
Bruker (NASDAQ: BRKR ) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $3.570 billion-$3.600 billion to $3.540 billion-$3.570 billion vs $3.589
EARNINGS | Aug 04, 2026, 11:05 AM UTC
L
Bruker price target raised by $15 at TD Cowen, here's why
Bruker price target raised by $15 at TD Cowen, here's why
EQUITY | Jul 15, 2026, 12:44 PM UTC
L
BRKR Bruker expands infection detection portfolio with acquisition of metagenomic mngs disqver® platform for pathogenic microorganisms in bl
BRKR Bruker expands infection detection portfolio with acquisition of metagenomic mngs disqver® platform for pathogenic microorganisms in blood Bruker expands infection detection portfolio with acquisition of metagenomic
MNA | Jul 15, 2026, 11:01 AM UTC
M
Guggenheim Maintains Buy on Bruker, Raises Price Target to $70
Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ: BRKR ) with a Buy and raises the price target from $50 to $70.
EQUITY | Jun 29, 2026, 01:57 PM UTC
M
BRKR: Barclays Raises Target
Barclays maintains overweight rating on Bruker and raises price target to $60
EQUITY | Jun 24, 2026, 02:32 PM UTC